DMP evaluation reports
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication KHK 2025.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication DM1 2025.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication COPD 2025.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication BK (breast cancer) 2025.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication ASB 2023.